2016 American Transplant Congress
Reduced-Dose Cidofovir (CID) and CMV-Hyperimmune Globulin (CMVIg) for Ganciclovir-Resistant Cytomegalovirus: Effective and Kidney Friendly.
Houston Methodist Hospital, Houston, TX.
Ganciclovir resistant (GR) CMV is associated with an aggressive disease course and substantial morbidity. Furthermore, treatment options such as foscarnet and cidofovir are incredibly nephrotoxic.…2016 American Transplant Congress
Prophylactic Anti-Virus Therapy, Is It Necessary to Occult Hepatitis B Virus Carriers with HBsAg(-) and HBcAb(+) After Kidney Transplantation?
Background Hepatitis B virus(HBV) infection is common among uremia patients in China. Many patients received kidney transplantation are occult HBV carriers with HBsAg(-) and HBcAb(+)…2016 American Transplant Congress
Descriptive Epidemiology and Trends of Community Parenteral Antimicrobial Therapy Utilization Among Solid Organ Transplant Recipients at a High Volume Transplant Center 2008 to 2014.
Infectious Diseases, Cleveland Clinic, Cleveland, OH.
INTRODUCTION: Solid organ transplant (SOT) recipients may benefit from community-based parenteral anti-infective therapy (CoPAT). Limited data are available. CoPAT may help reduce LOS. As a…2016 American Transplant Congress
Is SVR Associated with Improved Hepatic Function in Hepatitis C Gen 1 Pts with Cirrhosis 1 Year After Completing Treatment with Sofosbuvir + Simeprevir +/- Ribavirin?
Background: Combination antiviral therapy involving Sofosbuvir (SOF) & Simeprevir (SIM) +/- Ribavirin (RBV) is a relatively safe & effective Tx option in pts with gen…2016 American Transplant Congress
Safety and Efficacy of Ledipasvir/Sofosbuvir (LS) with or without Ribavirin (RBV) for Treatment of Recurrent Hepatitis C Infection Post-Liver Transplant.
Mulit-Organ Transplant Institute, Ochsner Medical Center, New Orleans, LA.
Background: Hepatitis C (HCV) is the most common indication for liver transplant in the United States representing more than 40% of all recipients. Availability of…2016 American Transplant Congress
Potential Biomarkers and Treatment for BK Virus Associated Nephropathy.
Background: BK polyomavirus assoiciated nephropathy (BKVAN) is one of the major complications in renal transplants, and is associated with significant fibrosis It is important to…2016 American Transplant Congress
Large Single-Center Experience of Sofosbuvir and Ledipasvir Therapy for the Treatment of Post-Liver Transplant Patients with Hepatitis C Virus.
Medicine, Emory University, Atlanta, GA.
Background/Aims: Controlled trials of direct acting antiviral therapy for Hepatitis C Virus (HCV) show impressive sustained virologic response (SVR) rates, but post-transplant data of sofosbuvir…2016 American Transplant Congress
Successful Treatment of Hepatitis C in Renal Transplant Recipients with Directly Acting Antiviral Agents.
Background: Hepatitis C infection (HCV) in kidney transplant (KTx) recipients has been shown to be a risk factor for decreased patient and allograft survival. With…2016 American Transplant Congress
Autologous BK-Specific T-Cell Lines in Kidney Transplant Recipients.
Background: More than 75% of the population has been exposed to BK polyomavirus and carries latent virus in the uroepithelium. Immunocompetent hosts are asymptomatic but…2015 American Transplant Congress
Incidence of CMV Viremia in Obese and Morbidly Obese Kidney Transplants Under a Low Dose Valganciclovir Prophylaxis Protocol
1Pharmacy Practice, Univ of IL-Chicago, Chicago, IL; 2Surgery, Univ of IL-Chicago, Chicago, IL.
Background: The rate of Cytomegalovirus infections in kidney transplant recipients drastically diminished with the advent of oral ganciclovir and subsequently valganciclovir. However it continues to…
American Transplant Congress abstracts